Q3 2025 Evonik Industries AG Earnings Call Transcript
Key Points
- Evonik Industries AG (EVKIF) is confident in achieving its revised EBITDA guidance of around €1.9 billion for the year, supported by strong demand in the healthcare segment and improved visibility in order bookings.
- The company has made significant progress in reducing its workforce, with 740 fewer full-time employees compared to the previous year, which is expected to contribute to cost savings.
- Evonik Industries AG (EVKIF) is on track to meet its free cash flow guidance, with a positive free cash flow of around €300 million in Q3 and further reductions in working capital expected in Q4.
- The company is progressing well with its infrastructure carve-out project, which is expected to reduce future capital expenditures and streamline operations.
- Evonik Industries AG (EVKIF) is optimistic about the future contributions from its new lipid plant in the United States, which aligns with reshoring initiatives and is expected to enhance EBITDA in the long term.
- Evonik Industries AG (EVKIF) faced a weak Q3, with demand remaining very weak across all segments and markets, leading to a reduction in full-year guidance.
- The company experienced a significant decline in EBITDA for its advanced technologies segment, attributed to inventory reductions and maintenance shutdown costs.
- There is increased competition from Chinese imports in certain product areas, such as silica and crosslinkers, impacting demand and pricing in Europe.
- The methionine market remains challenging, with potential new capacities coming online that could suppress prices, despite improvements in cost positions.
- The overall macroeconomic environment is expected to remain challenging into 2026, with uncertainties around global trade dynamics and economic conditions.
Ladies and gentlemen, welcome to the Ivoe Industries AK Q3 2025 earnings conference call. I'm Matilda, the courses call operator.
I would like to remind you that all participants will be in listen-only mode and the conference is being recorded. (Operator Instructions)
The conference must not be recorded for publication or broadcast.
At this time it's my pleasure to hand over to Christian Kullman, CEO. Please go ahead.
Thanks a lot and welcome to our Q Q3 earnings call. Looking around in our boardroom, I see a very different setup here today. First of all, welcome to Klaus Reti, our interim CFO who is setting left to me.
Many of you already know him.
In his previous roles, he represented Yvonic at many investor conferences and capital markets. His extensive experience and knowledge of our companies helping us in his new role.
While the search for our CFO is ongoing.
I would like to take the opportunity here today to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
